Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial–Mesenchymal Transition

Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial–Mesenchymal Transition

Most epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) cells are killed within a few days after osimertinib treatment; however, surviving cells remain detectable and are called drug-tolerant cells. Plasminogen activator inhibitor-1 (PAI-1) was reported to be involved...

Full description

Bibliographic Details
Main Authors: Kentaro Tokumo, Takeshi Masuda, Taku Nakashima, Masashi Namba, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Shintaro Miyamoto, Hiroshi Iwamoto, Kazunori Fujitaka, Yoshihiro Miyata, Morihito Okada, Hironobu Hamada, Noboru Hattori
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cancers
Subjects:
epidermal growth factor receptor
plasminogen activator inhibitor-1
drug-tolerant cells
non-small-cell lung cancer
epithelial–mesenchymal transition
Online Access:https://www.mdpi.com/2072-6694/15/4/1092

Internet

https://www.mdpi.com/2072-6694/15/4/1092

Similar Items